Cognitive decline due to Alzheimer's disease (AD) is closely associated with brain structure alterations captured by structural magnetic resonance imaging (sMRI). It supports the validity to develop sMRI-based univariate neurodegeneration biomarkers (UNB). However, existing UNB work either fails to model large group variances or does not capture AD dementia (ADD) induced changes. We propose a novel low-rank and sparse subspace decomposition method capable of stably quantifying the morphological changes induced by ADD. Specifically, we propose a numerically efficient rank minimization mechanism to extract group common structure and impose regularization constraints to encode the original 3D morphometry connectivity. Further, we generate regions-of-interest (ROI) with group difference study between common subspaces of Aβ+AD and Aβ-cognitively unimpaired (CU) groups. A univariate morphometry index (UMI) is constructed from these ROIs by summarizing individual morphological characteristics weighted by normalized difference between Aβ+AD and Aβ-CU groups. We use hippocampal surface radial distance feature to compute the UMIs and validate our work in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. With hippocampal UMIs, the estimated minimum sample sizes needed to detect a 25% reduction in the mean annual change with 80% power and two-tailed P=0.05are 116, 279 and 387 for the longitudinal Aβ+AD, Aβ+mild cognitive impairment (MCI) and Aβ+CU groups, respectively. Additionally, for MCI patients, UMIs well correlate with hazard ratio of conversion to AD (4.3, 95% CI = 2.3-8.2) within 18 months. Our experimental results outperform traditional hippocampal volume measures and suggest the application of UMI as a potential UNB.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725891 | PMC |
http://dx.doi.org/10.1016/j.media.2020.101877 | DOI Listing |
Alzheimers Res Ther
January 2025
Fraunhofer Institute for Algorithms and Scientific Computing SCAI, Sankt Augustin, Germany.
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder affecting millions worldwide, leading to cognitive and functional decline. Early detection and intervention are crucial for enhancing the quality of life of patients and their families. Remote Monitoring Technologies (RMTs) offer a promising solution for early detection by tracking changes in behavioral and cognitive functions, such as memory, language, and problem-solving skills.
View Article and Find Full Text PDFNeurol Neuroimmunol Neuroinflamm
January 2025
From the Neurology-Neuroimmunology Department (J.V.-Á., V.F., A.V., M. Castillo, M. Comabella), Multiple Sclerosis Center of Catalonia, Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Research Institute; Autonomous University of Barcelona (M. Comabella), Spain; Department of Neurology with Institute of Translational Neurology (J.D.L.), University Hospital Münster, Germany; Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., Y.B.), Hospital Clinic de Barcelona; Fundación INCE (Iniciativa para las Neurociencias) (A.V.-C.), Madrid, Spain; Neurology Unit (A.D., S.M.), Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy; Neuroimmunology Program (S.L., Y.B., T.A.), Neurology Service, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic de Barcelona; Pediatric Neuroimmunology Unit (T.A.), Neurology Department, Sant Joan de Déu Children's Hospital, University of Barcelona; Girona Neuroimmunology and Multiple Sclerosis Unit (G.Á.B., L.R.), Neurology Department, Dr. Josep Trueta University Hospital and Santa Caterina Hospital; Neurodegeneration and Neuroinflammation research group (G.Á.B., A.Q.-V., L.R.), IDIBGI, Girona-Salt; Department of Medical Sciences (G.Á.B., L.R.), Faculty of Medicine, University of Girona; and Redes de Investigación Cooperativa Orientada a Resultados en Salud (RICORS) (A.Q.-V., L.R.), Red de Enfermedades inflamatorias (RD21/0002/0063), Instituto de Salud Carlos III, Madrid, Spain.
Background And Objectives: The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis and prognosis are lacking. We aimed to investigate the value of complement factors (CFs) as diagnostic and prognostic biomarkers in patients with MOGAD.
Methods: Multicentric retrospective cohort study including patients with MOGAD, multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD) with available paired serum and CSF samples.
NPJ Parkinsons Dis
November 2024
Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA.
Alterations in subcortical brain regions are linked to motor and non-motor symptoms in Parkinson's disease (PD). However, associations between clinical expression and regional morphological abnormalities of the basal ganglia, thalamus, amygdala and hippocampus are not well established. We analyzed 3D T1-weighted brain MRI and clinical data from 2525 individuals with PD and 1326 controls from 22 global sources in the ENIGMA-PD consortium.
View Article and Find Full Text PDFJ Huntingtons Dis
September 2024
Departments of Neurology and Division of Neurobiology, Department of Psychiatry JHUSOM, Baltimore, MD, USA.
Metabolites
July 2024
Department of Chemistry and Biochemistry, Montana State University-Bozeman, Bozeman, MT 59717, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!